Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer.
Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer.
复制标题
DOI：
10.1007/s10549-009-0495-x
复制
发表时间：
2010-01
影响因子：
3.8
通讯作者：
Fabian, Carol J.
中科院分区：
文献类型：
--
作者：
Khan, Qamar J.;Reddy, Pavan S.;Kimler, Bruce F.;Sharma, Priyanka;Baxa, Susan E.;O'Dea, Anne P.;Klemp, Jennifer R.;Fabian, Carol J.
关键词：
维生素D缺乏和不足可能导致服用芳香酶抑制剂(AIS)的女性出现肌肉骨骼症状和骨质丢失。这项研究是为了确定接受来曲唑辅助治疗乳腺癌的女性中维生素D水平低于最佳水平的患病率，并确定每周补充50IU维生素D3是否可以减轻维生素D水平低于最佳水平的女性的肌肉骨骼症状和疲劳。60名即将开始人工智能佐剂的女性被招募进来。获得基线25OHD水平，妇女完成症状问卷调查。然后，他们开始服用来曲唑，以及标准剂量的钙和维生素D。四周后，基线≤水平为40 ng/ml的妇女开始补充维生素D3，每周50,000国际单位，持续12周。在第4周、第10周和第16周重新评估25OHD水平；在第4周和第16周重复问卷调查。在基线水平，63%的女性表现出维生素D缺乏(20 ng/ml)或不足(20-31 ng/ml)。在42名每周补充50000国际单位维生素D3的受试者中，所有的受试者都达到了40 ng/ml的摄氧量，没有任何不良反应。服用来曲唑16周后，25OHD水平为66 ng/ml(中位数)的女性报告没有关节疼痛致残的女性比水平为66 ng/ml的女性更多(52%对19%；P=0.026)。维生素D缺乏和不足在绝经后启动人工智能佐剂的妇女中普遍存在。每周补充50000国际单位的维生素D3是安全的，显著增加25OHD水平，并可能减少AI诱导的关节痛的残疾。
Vitamin D deficiency and insufficiency may contribute to musculoskeletal symptoms and bone loss observed in women taking aromatase inhibitors (AIs). This study was conducted to determine the prevalence of suboptimal vitamin D levels in women initiating adjuvant letrozole for breast cancer and to determine whether supplementation with 50,000 IU of vitamin D3 weekly could reduce musculoskeletal symptoms and fatigue in women who have suboptimal vitamin D levels. Sixty women about to begin an adjuvant AI were enrolled. Baseline 25OHD levels were obtained, and women completed symptom questionnaires. They were then started on letrozole, along with standard dose calcium and vitamin D. Four weeks later, women with baseline 25OHD levels ≤40 ng/ml started additional vitamin D3 supplementation at 50,000 IU per week for 12 weeks. 25OHD levels were re-assessed at 4, 10, and 16 weeks; the questionnaires were repeated at weeks 4 and 16. At baseline, 63% of women exhibited vitamin D deficiency (<20 ng/ml) or insufficiency (20–31 ng/ml). 25OHD levels >40 ng/ml were achieved in all 42 subjects who received 12 weeks of supplementation with 50,000 IU vitamin D3 weekly, with no adverse effects. After 16 weeks of letrozole, more women with 25OHD levels >66 ng/ml (median level) reported no disability from joint pain than did women with levels <66 ng/ml (52 vs. 19%; P = 0.026). Vitamin D deficiency and insufficiency are prevalent in post-menopausal women initiating adjuvant AI. Vitamin D3 supplementation with 50,000 IU per week is safe, significantly increases 25OHD levels, and may reduce disability from AI-induced arthralgias.
登录
查看更多内容
影响因子：
4.2
作者：
Hanley, DA;Davison, KS
通讯作者：
Davison, KS
影响因子：
45.3
作者：
Partridge, Ann H.;LaFountain, Andrea;Asnis-Alibozek, Aviva
通讯作者：
Asnis-Alibozek, Aviva
影响因子：
45.3
作者：
Coates, Alan S.;Keshaviah, Aparna;Goldhirsch, Aron
通讯作者：
Goldhirsch, Aron
影响因子：
--
作者：
Wolfe, F;Michaud, K;Pincus, T
通讯作者：
Pincus, T
影响因子：
5.8
作者：
Holick, MF;Siris, ES;de Papp, AE
通讯作者：
de Papp, AE